UK Biotech

UK bank launches £2.5B plan to fund innovation, with a special place for its long-ailing biotech scene

Can a government-owned bank loaded with cash help trigger a biotech boom in the UK?

We’ll find out.

The British Business Bank has just unveiled a £2.5 billion scheme to invest in “innovative” companies in the UK, and they have a special focus on drug discovery and development.

The BBB is transferring £400 million over to the newly created British Patient Capital to get things going. And they’re starting with a small, £9 million investment in the Dementia Discovery Fund, which is backing life sciences companies in the field. Another £30 million goes to Draper Esprit’s £115 million capital raise.

The idea here is that the government can inspire investments totaling three times their £2.5 billion investment. 

The UK’s Golden Triangle is home to some of the world’s best known scientists, and has a major backer with AstraZeneca and GSK based in the country. But there’s also a strong underlying belief that the country lacks the kind of experienced execs and financial support for the hub to break out of its limited boundaries.


Image: London. SHUTTERSTOCK


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription


Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->